Kyntra Bio (NASDAQ:KYNB) Stock Rating Upgraded by Zacks Research

Kyntra Bio (NASDAQ:KYNB) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Several other analysts also recently weighed in on the company. Weiss Ratings downgraded Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price target on shares of Kyntra Bio in a research note on Tuesday, September 1st. Maxim Group started coverage on shares of Kyntra Bio in a research note on Tuesday, October 13th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Lake Street Capital assumed coverage on shares of Kyntra Bio in a report on Thursday, September 17th. They set a “buy” rating and a $41.00 price objective for the company. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kyntra Bio has an average rating of “Moderate Buy” and an average price target of $36.80.

Kyntra Bio Stock Up 3.1%

Shares of Kyntra Bio stock opened at $3.68 on Tuesday. The stock’s fifty day moving average is $6.04 and its two-hundred day moving average is $6.92. The company has a market capitalization of $14.90 million, a PE ratio of 0.08 and a beta of 1.08. Kyntra Bio has a 52 week low of $3.50 and a 52 week high of $10.47.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new stake in Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio as of its most recent filing with the SEC. Institutional investors and hedge funds own 72.71% of the company’s stock.

Kyntra Bio Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.